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 Introduction 
 Uveitis is a leading cause of visual impairment and a 
significant burden of legal and economic blindness  [1] . It 
affects predominantly young working-age individuals 
and consequently has a large impact on society and health 
care  [1] . This is particularly true for inflammation of the 
posterior part of the eye. In general, uveitis encompasses 
a very diverse group of inflammatory ocular diseases that 
are differentiated based on the primary location of the 
inflammation within the eye. Whereas anterior uveitis is 
the most frequent type of intraocular inflammation, more 
severe problems are related to intermediate uveitis, pos-
terior uveitis and panuveitis  [2] . Another important clas-
sification is related to its infectious or noninfectious etiol-
ogy, because this will obviously result in completely dif-
ferent therapeutic approaches. Initial treatment in acute 
noninfectious intermediate and posterior uveitis is based 
predominantly on corticosteroids. It has been proposed 
that up to two thirds of patients with posterior uveitis can 
be controlled on steroids alone. However, many patients 
are intolerant to long-term-applied systemic steroids, and 
immunomodulatory treatment is commonly suggested as 
steroid-sparing agents. Notably, even though the addi-
tion of immunosuppressive agents is often effective as a 
corticosteroid-sparing approach, most patients do not 
 Key Words 
 Corticosteroids · Dexamethasone implant · Intravitreal 
injection · Ozurdex · Uveitis 
 Abstract 
 Purpose: To investigate the efficacy and safety of a single 
dexamethasone intravitreal implant (Ozurdex ® , 700 μg). 
 Methods: In this prospective noncomparative case series, 84 
patients (54 females) received a dexamethasone intravitreal 
implant. At weeks 4, 12 and 24 after the injection, vitreous 
haze, macular thickness and best corrected visual acuity 
(BCVA) were assessed and adverse events reported.  Results: 
Clearance of vitreous haze could be achieved after 4 weeks 
in 61% of all eyes (p < 0.001) and remained significant until 
week 24 (p < 0.001). This was paralleled by a reduction of 
central retinal thickness after 4 (p < 0.001), 12 (p < 0.001) and 
24 weeks (p < 0.006). Significant and fast improvement of 
BCVA was already achieved after 4 weeks (p < 0.001) but van-
ished by week 24. Intraocular pressure reached  ≥ 35 mm Hg 
in 3 eyes and was significantly more frequent in intermediate 
uveitis compared to posterior uveitis (p < 0.016).  Conclu-
sions: The dexamethasone implant is effective in controlling 
intraocular posterior segment inflammation and reduces 
central retinal thickness fast and effectively. 
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achieve additional visual improvement through their ad-
dition  [3] . Therefore, attempts to attain effective steroid 
levels in the vitreous and retina remain an important 
treatment goal. 
 While subconjunctival or peribulbar injections of ste-
roids give rise to a short-term and often uncertain thera-
peutic concentration in the vitreous cavity, intravitreal 
injections have become an accepted route to deliver ther-
apeutic agents directly to the choroid and retina  [4] . Ex-
perimental and clinical data indicate that the direct ad-
ministration of steroids, such as triamcinolone, into the 
vitreous cavity has significant benefits in the delivery of 
medication to the posterior segment, in particular the 
macula and optic nerve  [5] . By this means, corticosteroids 
reach higher therapeutic concentrations for the adequate 
treatment of posterior segment inflammation  [6] . How-
ever, frequent injections are often needed to maintain the 
drug concentrations within a therapeutic range in the 
posterior segment. To circumvent the disadvantages of 
short-acting intravitreal or systemic administration, drug 
delivery systems for vitreoretinal disorders using biode-
gradable or nonbiodegradable devices have been intro-
duced  [7–9] .
 Subsequently, an intravitreal dexamethasone device 
(Ozurdex ® ; Allergan, Irvine, Calif., USA) has been ap-
proved. The HURON study concluded that Ozurdex was 
effective in controlling uveitis and macular edema with a 
good safety record in eyes that had intermediate or pos-
terior uveitis  [7] . However, the trial entry criteria for the 
HURON study were stringent, e.g. suspected steroid re-
sponders were excluded and only a single dexamethasone 
intravitreal implant injection was given. However, with 
regard to daily clinical needs, which might be different 
from the study situation, more clinical experience and in-
formation seems mandatory. Therefore, the goal of the 
present study is to report clinical findings following a sin-
gle dexamethasone intravitreal implant injection in a sub-
stantial number of patients and compare them with the 
limited information available so far. 
 Methods 
 This prospective observational study included patients treated 
with a dexamethasone intravitreal implant (Ozurdex) for nonin-
fectious intermediate and posterior uveitis. Patients aged  ≥ 18 
years with vitreous haze and/or macular edema were enrolled in 
the study. A systemic workup included laboratory testing, anterior 
chamber taps and radiographic imaging as needed to identify in-
fectious and noninfectious etiologies. All patients underwent a 
comprehensive ocular examination including anterior and poste-
rior segment evaluation, intraocular pressure (IOP; Goldmann ap-
planation) and central retinal thickness measurements via optical 
coherence tomography (OCT; Carl Zeiss, Oberkochen, Germany). 
We recorded the demographics, etiology of inflammation, best 
corrected visual acuity (BCVA), clinical examination and prior 
therapies of the patients. The approval of the Institutional Review 
Board for Human Subjects Research was obtained at both insti-
tutes to review the data. The research is adhered to the tenets of the 
Declaration of Helsinki. After informed consent was obtained 
from the patients, the dexamethasone intravitreal implant was ad-
ministered in accordance with the manufacturer’s instructions us-
ing the 22-gauge applicator device. 
 All patients were routinely scheduled for complete ocular ex-
ams at the first day after application and 4, 12 and 24 weeks after 
the injection. To allow for the comparison of previous results with 
our clinical findings, outcome measures have been adopted ac-
cordingly. In particular, the main outcome measures such as vitre-
ous haze and safety concerns were followed at appropriate time 
intervals. In addition, we report OCT measurements, which were 
obtained at all control visits.
 The primary outcome measure was based on the degree of vit-
reous haze and the proportion of patients with completely cleared 
vitreous haze (haze score = 0). Vitreous haze was evaluated using 
a standardized photographic scale ranging from 0 to 4 as previ-
ously established  [2] . BCVA was measured using the logMAR 
scale. Safety parameters, including adverse events at any time 
point, focused particularly on IOP assessments, changes in lens 
opacification and any findings on slit-lamp biomicroscopy or oph-
thalmoscopy.
 Statistical Analysis 
 For comparisons between treatment centers, baseline demo-
graphic and clinical values were analysed using either Pearson’s χ 2 
test or the t test. To assess the efficacy of treatment and to calculate 
between group differences (intermediate vs. posterior uveitis) a 
general linear model was constructed utilizing a two-factorial re-
peated-measures ANOVA. General linear model factors and con-
trasts were defined as follows: within-subject factor = study week 
with simple contrasts; between-subject factor = diagnosis (inter-
mediate vs. posterior uveitis) with repeated contrasts. Mauchly’s 
test for sphericity of data was performed, and, if significant, the 
Greenhouse-Geisser correction for degrees of freedom was used. 
The Bonferroni correction was used to adjust for multiple com-
parisons. A p value of  ≤ 0.05 was deemed a statistically significant 
result. The statistical software package used was SPSS v19.0 (IBM).
 Results 
 Demographics 
 Eighty-four eyes of 84 patients were included in the 
study. Patient demographics, diagnosis and examination 
findings are summarized in  table  1 . A postrecruitment 
analysis did not show a significant difference in the inclu-
sion criteria between the two participating clinical cen-
ters, Charité – University Medicine Berlin (Charité) and 
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line values of vitreous haze, mean central macular thick-
ness and initial IOP were comparable; however, age dis-
tribution between the treatment centers was significantly 
different (p = 0.005). On average, the Charité recruited 
older patients, presumably by chance. At baseline, no dif-
ference could be detected regarding vitreous haze or OCT 
measurements comparing patients with either intermedi-
ate or posterior uveitis. All patients could be followed for 
at least 6 months. 
 The mean age of our patients was 52.9 ± 17.5 years, 
there was a female predominance (64.3%), and all indi-
viduals were Caucasians. Forty-three (51%) patients were 
affected by intermediate uveitis and 41 (49%) by poste-
rior uveitis. The duration of the disease could not be 
clearly identified in all patients, and the onset of (e.g. in-
termediate) uveitis was frequently protracted. No under-
lying etiology could be identified in the patients with in-
termediate uveitis. However, further differentiation in 
those with posterior uveitis included sarcoidosis (11.9%), 
birdshot chorioretinopathy (9.5%), retinal vasculitis 
(9.5%), as well as multifocal choroiditis and panuveitis 
(2.4%). 
 Vitreous Haze 
 At baseline, the majority of patients had a vitreous 
haze score of 1.0 or 1.5. These relatively low haze scores 
are in part related to the fact that in several patients cys-
toid macular edema (CME) has been the primary indica-
tion. Thus, in these individuals vitreous haze was fre-
quently low at baseline. Following implantation, the per-
centage of patients with a score of 0 was significantly 
greater after 4 weeks (p < 0.001) than before treatment (51 
vs. 16 patients). The percentage of patients with a vitreous 
haze score of 0 was also significantly reduced at all subse-
quent time points during the 24-week follow-up period. 
The mean vitreous haze score was significantly reduced 
at all time points following intravitreal dexamethasone 
implantation ( fig. 1 ). When a subgroup analysis was per-
formed, patients affected by intermediate uveitis tended 
to have higher vitreous haze scores than those affected by 
posterior uveitis ( fig. 2 ). However, there was no signifi-
cant difference between the two groups (p = 0.336).
 Central Macular Thickness 
 At baseline, the mean central macular thickness was 
significantly increased with a mean thickness of 463 ± 
164.8 μm. A significant decrease of OCT measurements 
(p < 0.001) could be confirmed in most patients and 
reached a minimum thickness of 299.5 ± 109.7 μm al-
ready at the 4-week control visit. This effect remained sig-
nificant over the complete follow-up period ( fig. 3 ).
 Visual Acuity 
 Mean baseline acuity for all patients was 0.68 ± 0.47 
logMAR (20/100), which improved significantly to 0.53 
± 0.54 logMAR (20/63) after 4 weeks (p = 0.001), and to 
0.51 ± 0.49 logMAR (20/63) after 12 weeks (p < 0.001). 
The peak of maximum visual acuity gain was at week 4. 
 Table 1.  Demographic data of the participating individuals and study center comparison
Study aggregate Charité LMU p values
Patients 84 55 (65.5) 29 (35.5)
Age 52.9 ± 17.5 57.3 ± 13.3 44.6 ± 21.3 0.005
Sex
Male 30 (35.7) 17 (30.9) 13 (44.8) 0.206
Female 54 (64.3) 38 (69.1) 16 (55.2)
Diagnosis
Intermediate uveitis 43 (51.2) 29 (52.7) 14 (48.3) 0.698
Posterior uveitis 41 (48.8) 26 (47.3) 15 (51.7)
Vitreous haze score 0.89 ± 0.57 0.83 ± 0.54 1 ± 0.63 0.214
OCT, μm 462.8 ± 164.8 467.5 ± 157.6 454.6 ± 185.1 0.751
BCVA, logMAR 0.68 ± 0.47 0.62 ± 0.35 0.79 ± 0.62 0.186
Final visual acuity, logMAR 0.62 ± 0.52 0.62 ± 0.45 0.62 ± 0.63 0.984
IOP, mm Hg 13.9 ± 3.7 13.7 ± 3.6 13.5 ± 3.3 0.797
Phakic eyesa 36 (58.1) 21 (63.6) 15 (51.7) 0.409
 Values are presented as means ± SD or n (%). 
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However, this beneficial effect was lost at the last follow-
up (week 24; p = 0.999).  Figure 4 shows the distribution 
of lines gained and lost for the treated eyes. There was no 
significant difference between the two main diagnostic 
groups (intermediate vs. posterior uveitis).
 Reduction of Immunomodulatory Therapy/
Concomitant Systemic Steroids 
 Among the 84 patients, 32 (38%) were receiving sys-
temic immunomodulatory medication with or without 



























 Fig. 1. Bar graph showing the number of eyes with a vitreous haze 
score of 0 at baseline and after receiving a dexamethasone implant. 









































 Fig. 2. Analysis of the vitreous haze score following dexametha-
sone implantation. A significant reduction of the mean haze score 


























 Fig. 3. Box blots representing the first quadrile, median, and third 





























 Fig. 4. Analysis of the mean visual acuity (logMAR) before and af-
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individuals, systemic corticosteroid treatment could be 
discontinued and in 6 (19%) it could be substantially re-
duced (<10 mg). In the other patients, systemic immuno-
modulatory medication was continued during the study 
period. It has to be emphasized that these efforts were 
made to reduce the risk for recurrence of intraocular in-
flammation and that they were considered necessary for 
the treatment of the noninjected eye. An increase in anti-
inflammatory medication was not necessary in any of our 
patients. 
 Adverse Effects 
 Immediate ocular adverse events included conjuncti-
val hemorrhage in few patients, which cleared within sev-
eral days. One patient kept on anticoagulants experienced 
acute mild intravitreal bleeding, which subsided within 4 
weeks without affecting the visual function. There was no 
case of endophthalmitis or uveitis flare-up related to the 
implant.
 Secondary IOP Increase 
 Particular attention was paid to monitor the IOP in-
crease. At baseline, no patient had an IOP >21 mm Hg. 
Across all time points and all study visits, 3 patients (4%) 
developed an IOP of  ≥ 35 mm Hg and 13 (16%) had an 
IOP of  ≥ 25 mm Hg. The most significant IOP increase 
was observed at week 4 ( fig. 5 ). As a result of secondary 
IOP increase, the percentage of patients who required oc-
ular antihypertensive agents increased from 21% at base-
line and reached a maximum of 42% at week 12. A clear 
correlation to the steroid concentration could be detect-
ed, since the need for pressure-reducing agents subse-
quently regressed and only 28% eyes still needed antiglau-
comatous medication at week 24. Neither a laser nor any 
other invasive glaucoma procedure was required for pa-
tients with increased IOP. Interestingly, at follow-up, a 
subgroup analysis revealed that a diagnosis for intermedi-
ate uveitis was significantly associated with a stronger 
secondary IOP increase (p = 0.003;  fig. 6 ). At baseline, 
IOP did not differ between patients affected by interme-
diate uveitis and those affected by posterior uveitis.
 Cataract 
 At baseline, 35 eyes (42%) were already pseudophakic. 
Subcapsular cataract was present in 3 (6%) of 49 phakic 
eyes. During follow-up, these preexisting lens changes 
progressed in 2 eyes (4%) and mild subcapsular cataract 
was observed in 7 (14%) of the 49 phakic eyes. However, 
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 Fig. 5. Box blots representing the first quadrile, median, and third 
quadrile for each set of IOP measurements before and after dexa-
methasone implantation. F(2.91; 209.5) = 4.72; p = 0.004; η 2 = 
0.062; n = 74.  
 Fig. 6. Analysis of mean IOP (mm Hg) before and after dexameth-
asone implantation. A subgroup analysis demonstrates a signifi-
cantly (p < 0.006) stronger secondary IOP increase in patients af-
fected by intermediate uveitis as compared to those affected by 
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 It is well established that long-term follow-up of intra-
ocular inflammation in patients with minimal relapses re-
sults in a better visual prognosis than in patients with re-
peated episodes of intraocular inflammation  [10] . Com-
monly, immunomodulatory agents are introduced as 
steroid-sparing approach. However, undesired effects of 
these medications and the often excellent anti-inflamma-
tory effects of corticosteroids do often not allow a com-
plete cessation of steroid use  [11] . Therefore, develop-
ments of long-term, slow-release steroid devices that pro-
vide sustained control of intraocular inflammation 
without systemic adverse effects are an attractive option 
for many patients. Based on the available data on the phar-
macokinetics and pharmacodynamics of the sustained-
release dexamethasone drug delivery system, a peak drug 
concentration can be obtained until 4–8 weeks after injec-
tion, with the maximal concentration of >1,000 ng in the 
retina and >200 ng/ml in the vitreous at 8 weeks  [8] . These 
concentrations are highly effective to control acute in-
flammation and lymphocyte proliferation. Following the 
initial burst over the first 2 months, there is a steady de-
cline in steroid concentration until week 12, after which a 
second steady state is achieved and maintained until week 
24. This dynamic course is also reflected in our patients as 
seen in the clinical response to treatment. 
 In the present study, the implant effectively controlled 
intraocular inflammation over the 24-week follow-up 
 period. At all predetermined time points, a significant 
 reduction of vitreous haze could be achieved. In addi-
tion, the mean macular thickness decreased and BCVA 
improved for at least 3 months. These findings are in 
close concordance with previous observations from the 
HURON study  [7] . However, there are remarkable differ-
ences between the HURON study and our study that need 
a closer look.
 Almost half of our patients were affected by posterior 
uveitis. Among those, sarcoidosis, idiopathic retinal vas-
culitis, birdshot chorioretinopathy, and multifocal poste-
rior uveitis with panuveitis were the specific entities that 
responded well to treatment. In contrast, <20% of the eyes 
included in the HURON study were diagnosed with pos-
terior uveitis, and experience with the treatment effect 
remains limited so far. The proportional lower number of 
patients with intermediate uveitis in our cohort may ac-
count for the lower average vitreous haze score at base-
line, which subsequently led to a faster vitreous clearance. 
Already 4 weeks after treatment, more than 80% of our 
patients reached complete clearance without vitreous 
haze. This remarkable reduction remained significant 
across all time points at follow-up. 
 A significant number of our patients were affected by 
CME, which was the primary indication for the implant. 
A rapid decline of OCT measurements could be observed 
within 4 weeks when a maximum effect was already ob-
served. Even when this effect gradually vanished, it re-
mained highly significant. Notably, we reported a mean 
macular thickness of >450 μm, which was more than 100 
μm higher than the data reported in the HURON study 
 [7] .
 The reduced vitreous haze and particularly the de-
creased central macular thickness led to improved visual 
acuity in our patients. The reduced central macular thick-
ness was closely related to BCVA and reached its opti-
mum 4 weeks after the injection. Interestingly, whereas 
vitreous haze and macular thickness remained signifi-
cantly reduced over the complete observation period, no 
benefit on BCVA outcome could be observed at the last 
study visit. It might be assumed that the simultaneous 
change of both parameters led to this finding. A similar 
gradual decrease of functional effectiveness was observed 
in the HURON study  [7] . 
 As it might be expected, secondary IOP increase oc-
curred in a number of implanted eyes. Increased IOP was 
present in roughly every third patient (37%) at 4 weeks. 
The lower rate of IOP responders at the subsequent visits 
has to be carefully evaluated, since most of these patients 
received or remained on IOP medication during follow-
up. The higher incidence of increased IOP in our study 
was due to the inclusion of patients who already received 
antiglaucomatous agents at baseline. While these patients 
were excluded from the HURON study, such exclusion is 
often not possible in practical terms. Since only limited 
alternative treatment options are available, we carefully 
evaluated treatment options. All of our patients respond-
ed readily and well to topical treatment and none under-
went any further procedure. This is in concordance with 
currently available observations and seems not to in-
crease with repeated applications of the implant  [12, 13] . 
Interestingly, the risk of IOP increase was not equally dis-
tributed among indications. A significant proportion of 
eyes with intermediate uveitis developed pressure raise. 
The younger age of these patients as well as the more an-
terior location of the inflammatory process may be re-
sponsible for this observation, which needs further study. 
 During follow-up, cataracts were detected as adverse 
events in 2 (18%) of our phakic patients. This incidence 
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 In summary, our results demonstrate that a single 
dexamethasone intravitreal implant effectively controlled 
intraocular inflammation and improved the visual acuity 
in eyes with posterior segment inflammation. The onset 
of action was within 4 weeks and highly predictable in al-
most all of our patients. This fast response is likely to be 
related to drug release kinetics that peaks at this time, be-
fore a steady decline occurs. These pharmacokinetic fea-
tures are also responsible for the decrease in efficacy that 
restricts its effect to 4–5 months. The incidence of elevat-
ed IOP in implanted eyes was not unexpected. In accor-
dance with previous observations  [12–15] , this secondary 
effect could be managed in all patients with topical med-
ications. Even when presenting a relatively large cohort of 
patients, further data are needed to evaluate the use of the 
implant in particular subsets of disorders, e.g. birdshot 
chorioretinopathy. Finally, practitioners will need to bal-
ance the control of ocular inflammation observed with 
the intravitreal implant against the potential need for sys-
temic treatment.
 Disclosure Statement 
 None of the authors have a direct proprietary interest in any of 
the products used in this study.
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